ALLEGAN — Allegan-based Perrigo Co. (Nasdaq: PRGO) and Tris Pharma Inc. announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended-release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers’ store brands or own label brands.
Delsym, indicated for the temporary treatment of cough due to minor throat and bronchial irritation, has estimated annual sales of $100 million.
“We are excited to partner with Tris Pharma and bring this first ever store brand extended release liquid cough-cold product to our retail and store brand customers’ portfolios in time for the seasonm: said Perrigo chairman, president and CEO Joseph C. Papa. “This launch continues to demonstrate our commitment to making quality healthcare more affordable for consumers.”
Ketan Mehta, Tris’ CEO added, “When we developed our proprietary technology to deliver drugs in taste-neutral, extended release dosage forms such as liquids and ODT-chewable tablets, we were focused on improving the profile of new drugs. However, Delsym presented a unique opportunity where we were able to leverage our technology to bring a long overdue lower cost alternative to consumers and I am delighted we were able to partner with Perrigo to do so.”
From its beginnings as a packager of generic home remedies in 1887, Perrigo has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The company’s primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia.
More at Visit Perrigo at www.perrigo.com.
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable and strip dosage forms so patients do not have to swallow a pill. Tris’ Nobuse technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris’ R&D and manufacturing facilities are located in Monmouth Junction, N.J.
More at www.trispharma.com.